Liguang Q. Lou

Chinese Academy Of Sciences 555 Zuchongzhi Road
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion.

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion.

Journal: mAbs

Published: August 20, 2026

EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

Journal: Acta endocrinologica (Bucharest, Romania : 2005)

Published: April 01, 2025

A risk scoring model based on M2 macrophage-related genes for predicting prognosis of HBV-related hepatocellular carcinoma

A risk scoring model based on M2 macrophage-related genes for predicting prognosis of HBV-related hepatocellular carcinoma

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: June 11, 2024

Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors.

Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 25, 2023

Genomic structure of varicella-zoster virus and its vaccine application status

Genomic structure of varicella-zoster virus and its vaccine application status

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: February 16, 2023

Modular Biomimetic Strategy Enabled Discovery of Simplified Pseudo-Natural Macrocyclic P-Glycoprotein Inhibitors Capable of Overcoming Multidrug Resistance.

Modular Biomimetic Strategy Enabled Discovery of Simplified Pseudo-Natural Macrocyclic P-Glycoprotein Inhibitors Capable of Overcoming Multidrug Resistance.

Journal: Journal of medicinal chemistry

Published: February 02, 2023

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.

Journal: Molecular cancer therapeutics

Published: November 15, 2022

Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers.

Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers.

Journal: American journal of cancer research

Published: October 30, 2022

Discovery of novel heteroaryl alkynes for highly potent KITD816V cells inhibition to treat gastrointestinal stromal tumors.

Discovery of novel heteroaryl alkynes for highly potent KITD816V cells inhibition to treat gastrointestinal stromal tumors.

Journal: Acta pharmaceutica Sinica. B

Published: March 28, 2022

Trastuzumab in combination with PEGylated interferon-α1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.

Trastuzumab in combination with PEGylated interferon-α1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity.

Journal: American journal of cancer research

Published: October 08, 2021

TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models.

TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models.

Journal: American journal of cancer research

Published: January 15, 2021

Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.

Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.

Journal: Thoracic cancer

Published: December 30, 2020

Showing 1-12 of 48

Last Updated: 09/26/2026